Are there specific quality system implications for projects funded through non-dilutive means?

No, the quality system requirements, such as those outlined in FDA 21 CFR 820 or ISO 13485:2016, apply equally to all MedTech development projects, regardless of their funding source. Companies must maintain a robust quality management system to ensure product safety and effectiveness.

Can non-dilutive funding influence cybersecurity considerations for MedTech devices?

Indirectly, adequate non-dilutive funding can enable a MedTech company to invest sufficiently in cybersecurity measures, including those recommended by FDA guidance on premarket and postmarket cybersecurity management. This ensures resources are available for robust security development and maintenance.

All terms

Investment & FinanceStartup Lifecycle

Non-Dilutive Funding

Capital that does not require giving up equity, such as grants or debt.

Reviewed by Christian Espinosa, Founder, Blue Goat CyberLast reviewed May 5, 2026

Definition

Non-dilutive funding includes government grants (NIH SBIR/STTR, BARDA, ARPA-H), foundation grants, venture debt, revenue-based financing, and strategic milestone payments - capital that does not require issuing equity. Sources include government grants, foundation awards, contracts, prize competitions and some tax credits. Funding usually comes with reporting and use restrictions, and some programs claim rights to inventions. Non-dilutive money can extend runway and validate technology before an equity raise.

What the regulation says

While non-dilutive funding itself is not directly regulated, the use of such funds in MedTech is subject to the same regulatory requirements as any other funding source (e.g., FDA 21 CFR Part 820 for Quality System Regulation). Funding from government sources like NIH or BARDA often comes with specific reporting and compliance obligations related to project milestones and expenditures, distinct from general MedTech regulations.

What this means in practice

SBIR Phase I/II grants are a common MedTech bridge from idea to first equity round. Venture debt typically arrives after a Series B and extends runway with minimal dilution.

Examples

A MedTech startup receives an NIH SBIR grant to develop a novel diagnostic algorithm, which allows them to fund early-stage research and development without giving up equity before seeking venture capital.
A mature medical device company uses venture debt to expand its manufacturing capabilities for an existing Class II device, avoiding shareholder dilution while meeting increased market demand.
A small MedTech firm secures a BARDA contract to accelerate the development of a therapeutic device for pandemic preparedness, ensuring rapid prototyping and clinical trials without immediate equity financing.

Common pitfalls

•Confusing non-dilutive funding with a lack of financial oversight, as all financial activities within a MedTech company are subject to scrutiny during audits.
•Underestimating the administrative burden and reporting requirements associated with government grants, which can divert resources from core MedTech development activities.
•Failing to allocate non-dilutive funds appropriately to ensure compliance with quality system requirements (e.g., ISO 13485) throughout the product lifecycle.
•Assuming that non-dilutive funding implies less scrutiny on the scientific or technical merit of the MedTech innovation, as these funds often have rigorous review processes.

Frequently asked questions

The source of funding generally does not directly impact the content or review process of regulatory submissions, such as FDA 510(k) or PMA applications. However, strong financial backing, regardless of source, can demonstrate a company's ability to support post-market surveillance and other regulatory obligations.

Grouped by theme

Editor's picks

· Hand-selected related concepts

Investment & Finance

SBIR / STTR Grants(SBIR/STTR)

U.S. federal small-business R&D grants from agencies including NIH and DoD.

Investment & Finance

Venture Debt

Loan made to a venture-backed company, usually alongside or after equity.

Latest in MedTech

Sources

4 sources

Sources support the definition or relevant regulatory context, not necessarily every claim on this page. Each is graded against our source-tier hierarchy so you can see what rests on binding law versus commentary.

Tier 2Regulator guidance and consensus· 1Tier 3Peer-reviewed and registry evidence· 1Tier 4Trade press and expert commentary· 2

Link health: 4 verified· last checked 2026-06-20· added official documents checked 2026-11-01

NIH·1SVB·1PitchBook·1SEC·1

Inline markers like [1] jump to the matching reference above.

My progress

All terms0 / 513

Investment & Finance0 / 47

Saved on this device, and to your account when signed in. View studied terms

Full glossary

Browse all terms A to Z, each with a short definition.

On this term

Category: Investment & Finance
Sources: 4
Updated: 5/5/2026

Compare with another term

Learn in 60 seconds

Capital that does not require giving up equity, such as grants or debt.

·SBIR Phase I/II grants are a common MedTech bridge from idea to first equity round.
·Venture debt typically arrives after a Series B and extends runway with minimal dilution.
·Sources include government grants, foundation awards, contracts, prize competitions and some tax credits.

Remember this

Watch out: Confusing non-dilutive funding with a lack of financial oversight, as all financial activities within a MedTech company are subject to scrutiny during audits.

Related terms

You may also need

Auto-suggested from Investment & Finance and shared keywords.

All Investment & Finance terms